RESUMEN
Epidermal growth factor receptor inhibitors are anti-tumour agents that are frequently used for the treatment of neoplastic disorders. In addition to their cutaneous adverse effects, these drugs can rarely lead to erosive pustular dermatosis of the scalp. We report a case of a 67-year-old female who developed erosive pustular dermatosis of the scalp after being started on erlotinib from a trichoscopic perspective, which has been described in literature only once till now.
Asunto(s)
Antineoplásicos , Dermatosis del Cuero Cabelludo , Femenino , Humanos , Anciano , Dermatosis del Cuero Cabelludo/inducido químicamente , Dermatosis del Cuero Cabelludo/tratamiento farmacológico , Dermatosis del Cuero Cabelludo/patología , Clorhidrato de Erlotinib/efectos adversos , Cuero Cabelludo/patología , Antineoplásicos/uso terapéuticoAsunto(s)
Exantema , Dermatosis del Cuero Cabelludo , Enfermedades Cutáneas Vesiculoampollosas , Humanos , Panitumumab/efectos adversos , Cuero Cabelludo , Dermatosis del Cuero Cabelludo/inducido químicamente , Dermatosis del Cuero Cabelludo/tratamiento farmacológico , Enfermedades Cutáneas Vesiculoampollosas/inducido químicamente , Enfermedades Cutáneas Vesiculoampollosas/tratamiento farmacológicoRESUMEN
Gefitinib is a selective tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) used for the treatment of malignant neoplasms. The most frequent skin complication during gefitinib therapy is an acneiform papulopustular eruption, usually distributed in the seborrheic areas but occasionally widespread. We report a patient with erosive pustular dermatosis of the scalp, a neutrophil-mediated skin disease presenting with sterile pustules evolving into erosions and crusts on the scalp, during treatment with the EGFR inhibitor gefitinib for lung cancer. A literature review of the drug-induced cases of this rare entity is provided.
Asunto(s)
Antineoplásicos/efectos adversos , Erupciones por Medicamentos/etiología , Gefitinib/efectos adversos , Dermatosis del Cuero Cabelludo/inducido químicamente , Enfermedades Cutáneas Vesiculoampollosas/inducido químicamente , Anciano de 80 o más Años , Humanos , MasculinoAsunto(s)
Dermatosis del Cuero Cabelludo , Enfermedades Cutáneas Vesiculoampollosas , Afatinib/efectos adversos , Receptores ErbB , Humanos , Cuero Cabelludo , Dermatosis del Cuero Cabelludo/inducido químicamente , Dermatosis del Cuero Cabelludo/diagnóstico , Dermatosis del Cuero Cabelludo/tratamiento farmacológicoAsunto(s)
Compuestos Azo/efectos adversos , Dermatitis Alérgica por Contacto/etiología , Tinturas para el Cabello/efectos adversos , Pruebas del Parche , Fenilendiaminas/efectos adversos , Dermatosis del Cuero Cabelludo/inducido químicamente , Dermatitis Alérgica por Contacto/diagnóstico , Interacciones Farmacológicas , Femenino , Humanos , Dermatosis del Cuero Cabelludo/diagnóstico , Factores de Tiempo , Adulto JovenAsunto(s)
Dermatosis del Cuero Cabelludo , Enfermedades Cutáneas Vesiculoampollosas , Humanos , Nivolumab/efectos adversos , Cuero Cabelludo , Dermatosis del Cuero Cabelludo/inducido químicamente , Dermatosis del Cuero Cabelludo/tratamiento farmacológico , Enfermedades Cutáneas Vesiculoampollosas/inducido químicamente , Enfermedades Cutáneas Vesiculoampollosas/diagnósticoAsunto(s)
Benzoquinonas/efectos adversos , Dermatitis Alérgica por Contacto/etiología , Aceites de Plantas/efectos adversos , Alérgenos/efectos adversos , Alopecia/tratamiento farmacológico , Benzoquinonas/inmunología , Reacciones Cruzadas/inmunología , Dermatitis Alérgica por Contacto/inmunología , Dermatosis Facial/inducido químicamente , Femenino , Humanos , Hidroquinonas/inmunología , Persona de Mediana Edad , Nigella sativa , Dermatosis del Cuero Cabelludo/inducido químicamenteAsunto(s)
Antitiroideos/efectos adversos , Carbimazol/efectos adversos , Displasia Ectodérmica/inducido químicamente , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Dermatosis del Cuero Cabelludo/inducido químicamente , Dermatosis del Cuero Cabelludo/congénito , Adulto , Femenino , Humanos , Recién Nacido , Embarazo , Complicaciones del Embarazo/tratamiento farmacológicoAsunto(s)
Anticonvulsivantes/efectos adversos , Erupciones por Medicamentos/etiología , Lamotrigina/efectos adversos , Seudolinfoma/inducido químicamente , Anticonvulsivantes/administración & dosificación , Niño , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/patología , Femenino , Humanos , Lamotrigina/administración & dosificación , Seudolinfoma/diagnóstico , Dermatosis del Cuero Cabelludo/inducido químicamente , Dermatosis del Cuero Cabelludo/diagnóstico , Dermatosis del Cuero Cabelludo/patologíaRESUMEN
BACKGROUND: An essential step in ensuring the toxicological safety of cosmetic or personal care products is the evaluation of the skin sensitizing potential of product ingredients. OBJECTIVE: We used a standardized protocol from cosmetic trade industry and consumer safety groups to evaluate the sensitization potential of ingredients in 3 commercially available cleansing conditioners. METHODS: A total of 33 ingredients were evaluated. Each ingredient underwent (1) dermatological evaluation, (2) in silico analysis for irritation and sensitization potential, and (3) a literature evaluation to determine risk of sensitization. Consumer exposure level was compared with the weight-of-evidence no-expected sensitization induction level for the constituent. If a no-expected sensitization induction level for a specific ingredient was not available, the dermal sensitization threshold approach was used. A margin of safety was calculated for each constituent. RESULTS: The margins of safety for all evaluated ingredients in the cleansing conditioners were greater than 1. CONCLUSIONS: This analysis indicates that exposure to the individual ingredients present in these cleansing conditioners would not be expected to induce dermal sensitization in a consumer under the examined exposure scenario.